SRF617 Is a Potent Inhibitor of CD39 with Immunomodulatory and Antitumor Properties

Michael C. Warren
Surface Oncology
June 1, 2023
Immunohorizons
https://pubmed.ncbi.nlm.nih.gov/37219538

This article is currently being updated. View its version on PubMed.

https://pubmed.ncbi.nlm.nih.gov/37219538

Research summary

This study evaluates SRF617, a fully human IgG4 antibody that inhibits CD39's ATPase activity. SRF617 enhances T-cell proliferation, dendritic cell maturation, and proinflammatory cytokine release from macrophages. In vivo, SRF617 shows antitumor activity in CD39-expressing xenograft models and modulates immune cell infiltration in the TME.

Key outcome of the study

SRF617 binds to human CD39 with high affinity, inhibiting its ATPase activity. It enhances T-cell proliferation, dendritic cell maturation, and cytokine release from macrophages. In vivo, SRF617 exhibits antitumor activity and modulates immune cell infiltration in the TME.

Model

Human CD39 Knockin mouse model developed to assess SRF617's in vivo efficacy and immunomodulatory effects. This model allowed for the evaluation of SRF617's impact on CD39 expression and immune cell dynamics within the TME.

TARGET:
Entpd1
Ectonucleoside triphosphate diphosphohydrolase-1

Keywords

Cancer immunotherapy, CD39 inhibition, Tumor microenvironment modulation, Immune cell activation

Technical specifications

Human CD39 Knockin mouse model, SRF617 antibody treatment, Immune cell profiling, TME analysis

Related products

Catalogue product

genO‑hCD39

The genO‑hCD39 mouse enables the in vivo efficacy assessment and profiling of immuno-oncology agents targeting the human immune checkpoint CD39 in fully immunocompetent mice.

Customized product

No items found.